Evidence map›Paper›PMID 31620932›Full record

ArticleInternational journal of clinical oncology2020

Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck.

Hidenori Kimura, Satoshi Hamauchi, Sadayuki Kawai, Yusuke Onozawa, Hirofumi Yasui, Aiko Yamashita, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Hidenori KimuraDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Satoshi HamauchiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Sadayuki KawaiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Yusuke OnozawaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Hirofumi YasuiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Aiko YamashitaDivision of Nutrition, Shizuoka Cancer Center, Shizuoka, Japan.
Hirofumi OgawaDivision of Radiation Oncology and Proton Therapy, Shizuoka Cancer Center, Shizuoka, Japan.
Tsuyoshi OnoeDivision of Radiation Oncology and Proton Therapy, Shizuoka Cancer Center, Shizuoka, Japan.
Tomoyuki KamijoDivision of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Yoshiyuki IidaDivision of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Tetsuro OnitsukaDivision of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Tomoya YokotaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan. t.yokota@scchr.jp.ORCID http://orcid.org/0000-0001-7327-7949
Shizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProphylactic percutaneous endoscopic gastrostomy (PEG) has been widely performed before concurrent chemoradiotherapy (CCRT) for locally advanced squamous cell carcinoma of the head and neck (LASCCHN) because severe oral mucositis and dysphagia induced by CCRT lead to difficulty with oral intake. However, it is controversial whether all patients require prophylactic PEG for adjuvant CCRT. This study evaluated predictive factors for the feasibility of oral intake in adjuvant CCRT for patients with LASCCHN.

methodsThis study retrospectively analyzed 117 LASCCHN patients who underwent surgery followed by adjuvant CCRT with cisplatin at Shizuoka Cancer Center between April 2008 and December 2018. To investigate predictive factors for the feasibility of oral intake, tumor factors, treatment factors and social factors were included in multivariate analyses.

resultsOf the 117 patients, 25 received total laryngectomy and 92 received other surgery. In multivariate analysis, total laryngectomy [HR (hazard ratio) 0.09, P = 0.001] and oral cavity of primary tumor location (HR 0.21, P = 0.031) were significantly associated with the feasibility of oral intake. Difficulty obtaining adequate nutrition via oral intake from initiation of CCRT until 1 year after its completion was significantly rarer in the total laryngectomy group than in the other surgery group (16% vs. 57%, P < 0.001).

conclusionOur study suggests that majority of patients who underwent total laryngectomy are able to maintain oral intake during adjuvant chemoradiotherapy.

Indexed as

Chemoradiotherapy, AdjuvantAdministration, OralAdultAgedAntineoplastic AgentsCisplatinDeglutition DisordersFeasibility StudiesFemaleGastroscopyGastrostomyHead and Neck NeoplasmsHumansLaryngectomyMaleMiddle AgedAntineoplastic AgentsCisplatinAdjuvant concurrent chemoradiotherapyFeasibility of oral intakeLocally advanced squamous cell carcinoma of the head and neckTotal laryngectomy

Identifiers

PMID31620932
OpenAlexW2981255458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.